Summit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Selective Antibiotic for the Treatment of CDI OXFORD, United Kingdom, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...

Summit’s Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection Microbiome-Sparing Action of Ridinilazole associated with Superiority over Vancomycin in Sustained Clinical Response Rate OXFORD, United Kingdom, June 20, 2016 (GLOBE NEWSWIRE) -- Summit...